
BBNX Stock Forecast & Price Target
BBNX Analyst Ratings
Bulls say
Beta Bionics is uniquely positioned in the market due to the potential of its revolutionary iLet Bionic Pancreas technology in the treatment of diabetes. The company has demonstrated consistent financial growth with a steady cadence of "beats and raises" and has a strong product offering with the iLet and Mint. Investors can expect a focus on cost reduction and continued sales force expansion to drive further revenue growth in the coming years.
Bears say
Beta Bionics is making progress in the development and launch of its iLet Bionic Pancreas and Mint patch pump, with an updated algorithm expected for launch in 4Q26. The company has received FDA clearance for Mint, which is expected to launch in 1Q27 and contribute to revenue growth. However, the company's financials remain a concern, with a negative adjusted EBITDA expected for FY26 and lowered revenue guidance due to a potential shift in patient launch preferences. As a financial analyst, a cautious approach is recommended towards this stock until there is more clarity on the company's financial performance and ability to generate profits.
This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.
BBNX Analyst Forecast & Price Prediction
Start investing in BBNX
Order type
Buy in
Order amount
Est. shares
0 shares